Fraud and corruption cost pharma 2.6% of revenues
This article was originally published in Scrip
Executive Summary
Healthcare, pharmaceutical and biotechnology companies on average lost 2.6% of their revenues because of fraud, according to the Global Fraud Report 2011/2012, conducted by the Economist Intelligence Unit. The pharma/biotech sector registered the second highest percentage loss of any industry, with only financial services companies faring worse.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.